Home
The U.S. FDA Approved Immunity Bio’s ANKTIVA® for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The U.S. FDA Approved Immunity Bio’s ANKTIVA® for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Today’s Highlights April 23, 2024

Immunity Bio in the NEWS
Immunity Bio (IBRX) - an immunotherapy company, announced that the U.S. FDA has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

Immunity Bio . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
April 23, 2024

Other Articles